



41ST ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Dalen Meeter, CFO | Eli Glezer, CSO

January 12, 2023

FORWARD-LOOKING STATEMENTS

All statements in this presentation and the associated discussion, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our ability to successfully manufacture and commercialize the G4 in accordance with our timelines, objectives and specifications; (ii) our ability to successfully ship G4 systems on our timeline; (iii) our ability to achieve customer and scientific acceptance of the G4; (iv) the market opportunities for our product offerings; and (v) the ability of our product offerings to successfully compete with existing and new products offered by our competitors. Any such forward-looking statements are based on our management's current expectations and are subject to risks and uncertainties that could cause our actual future results to differ materially from our management's current expectations or those implied by our forward-looking statements. These risks and uncertainties include, but are not limited to the following: (i) we have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to support our business plans and future operations; (ii) we have very little history manufacturing and commercializing our products or technology; (iii) the life sciences technology market is highly competitive, and if we fail to compete effectively, our business and operating results will suffer; (iv) if we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our products; (v) if our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed; (vi) we expect to be highly dependent upon revenue generated from the sale of the G4 and planned PX, and any delay or failure by us to successfully manufacture and commercialize the G4 and planned PX could have a substantial adverse effect on our business and results of operations; and (vii) the COVID-19 pandemic and efforts to reduce its spread have adversely impacted, and may materially and adversely impact, our business, operations, supply chain requirements, manufacturing and commercialization objectives. These and other risk factors that may affect our future results of operations are identified and described in more detail in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time, including our Quarterly Report on Form 10-Q for the period ended September 30, 2022, filed with the SEC on November 7, 2022. Accordingly, you should not rely on forward-looking statements as predictions of future events or our future performance. Except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

The performance information in this presentation and the associated discussion regarding our G4 instrument and test kits are reported at target specifications, and the performance of third-party instruments are reported based on specifications publicly available on such third party's website.

This presentation contains references to our trade names, trademarks and service marks and to those belonging to other third parties. We do not intend our use or display of a third party's trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, such third party.

SINGULAR THEMES

- | | | |
|---|----------------------------|--|
| 1 | G4 is On-Market | Customer success, resonating value proposition |
| 2 | Market Opportunity | Solutions for large and growing markets |
| 3 | Business Execution | Operational and commercial progress |
| 4 | Innovation Pipeline | New kits and instruments in development |

Speed

6–19 hours

Industry leading run times

Flexibility

1–4 flow cells
16 lanes

Unparalleled operational efficiency



Power

15–400 Gb output range

More data per day than any other
benchtop sequencer

Accuracy

75%–90% bases \geq Q30

State-of-the-art industry standard

Brand Awareness & Growth


Strong tradeshow & customer engagements

Value Proposition Resonating

Growing Marketing & Sales funnels

Customer Success

Multiple installations and positive feedback



ON-MARKET FEEDBACK

CUSTOMER QUOTES AND PHOTOS

"The **flexibility and speed** of the G4 has enabled our Spatial Technologies Unit to use a single instrument for new single cell and spatial transcriptomic assay pilots as well as production, decrease turnaround times, and meet demanding deadlines for our clients."

- **Ioannis Vlachos, Harvard University, BIDMC**




"... I'm blown away by the fact that we're able to get such **high-quality sequencing results** back in **less than a day!** We're looking forward to continuing to collaborate with Singular Genomics in 2023 and being able to share some of the exciting sequencing projects we're working on!"

- **Anthony Zamora, Medical College of Wisconsin**


"We were very **impressed with the training** provided by the Singular Genomics team and how **knowledgeable and helpful** everyone was. We're excited to provide sequencing services on the G4 in our core facility"

- **Scott Ness, University of New Mexico**






\$6B by Market






- Research & Translational
- Clinical
- Applied

\$6B by Application



- WGS
- WES
- Targeted
- RNA-Seq
- Other


Market	2022 TAM	G4 Addressable	G4 Value Proposition ¹
Research & Translational	\$3B		Flexibility Lane Independence Cost
Clinical	\$2B		Lane Independence Speed Scale
Applied	\$1B		Flexibility Speed Scale

G4 can deliver superior value to customers; current market is largely addressed by a single NGS provider


(1) New kits such as Max Reads, HD-Seq, Ring-Seq expected to drive further opportunities

SUPERIOR KPIs ACROSS CORE METRICS


POWER MAX GB PER HOUR




SPEED 300 CYCLE RUN TIME




FLEXIBILITY MAX LANES PER RUN



Delivering industry “gold standard” accuracy levels of up to 99.9% or Q30 for 75%–90% of base reads





In-house Development


*G4 platform enhancement pipeline
Novel SBS chemistry, multi-platform roadmap*


Lean Innovation

Capital efficient development

Growing Patent Portfolio

173 patents and applications





Supply Chain



Focusing on robustness and scalability


Scaling & Capacity

*Dedicated manufacturing facility
Capacity to support multi-year growth*

Robustness & Reliability

*Early placements performing
Commitment to continual improvement*





Experienced Sales & Marketing Team

Generating awareness, leads and growing funnel

Global Expansion

North America & Europe direct, distributors for ROW

Customer Success

Best-in-class Service & Support




Global Expansion Strategy:

1	North America
2	Europe
3	Rest of World

SEAMLESS WORKFLOW

ECOSYSTEM COMPATIBILITY FOR CUSTOMER ADOPTION



Prepare

Simple run planning and library loading



Sequence

Integrated clustering and sequencing



Analyze

Rapid and accurate analysis

16

Industry-leading library prep partners

>80%

Addressable library prep market enabled



S I N G U L A R
G E N O M I C S



Industry-leading data analysis partners




S I N G U L A R
G E N O M I C S

DATA GENERATION AND PUBLICATIONS

DATA-DRIVEN VALIDATION


3 Business Execution



Data Generation

3rd Party Validation & Publications






G4 Platform



2022

Additional Kits & Content



2023

PX Platform



2024 >

SINGULAR THEMES

MEASURING SUCCESS IN 2023

1 **G4 is On-Market**

Install base, customer satisfaction, revenue

2 **Market Opportunity**

Product fit, segments and applications

3 **Business Execution**

Reliability and scalability

4 **Innovation Pipeline**

G4 product pipeline, PX

SINGULAR GENOMICS – THANK YOU!

